ストックスクリーナーアプリを入手
67.96
2.04%
1.36
プレマーケット:
68.47
0.51
+0.75%
Astrazeneca PLC (AZN) 最新ニュース
UMB Bank n.a. Acquires 4,153 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Diversify Advisory Services LLC Cuts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
Arkadios Wealth Advisors Sells 3,786 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
2025-01-21 | Shareholders that lost money on AstraZeneca PLC(AZN) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:AZN | Press Release - Stockhouse Publishing
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - GlobeNewswire Inc.
ASTRAZENECA ALERT: Bragar Eagel & Squire, P.C. Announces - GlobeNewswire
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in AstraZeneca PLC. of Class Action Lawsuit and Upcoming DeadlinesAZN - PR Newswire
AstraZeneca PLC ADR rises Tuesday, outperforms market - MarketWatch
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients - Yahoo Finance UK
AstraZeneca, Daiichi’s Enhertu successor gets first FDA OK in breast cancer - BioPharma Dive
AstraZeneca rises Tuesday, outperforms market - MarketWatch
AstraZeneca PLC (AZN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
2025-01-21 | AstraZeneca PLC Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca PLC (NASDAQ:AZN) Holdings Lifted by Brookmont Capital Management - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by ZWJ Investment Counsel Inc. - MarketBeat
Investors who lost money on AstraZeneca PLC(AZN) should contact Levi & Korsinsky about pending Class ActionAZN - GuruFocus.com
AZN INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AstraZeneca PLC Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - PR Newswire
AstraZeneca PLC (NASDAQ:AZN) Receives Consensus Recommendation of "Buy" from Brokerages - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – AZN - Markets Insider
AstraZeneca Secures FDA Nod for New ADC Drug Datroway in Breast Cancer - Yahoo Finance
US Dato-DXd Approval Relief For AstraZeneca and Daiichi Sankyo - News & Insights
2025-01-20 | Levi & Korsinsky Reminds AstraZeneca PLC Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 21, 2025AZN | NDAQ:AZN | Press Release - Stockhouse Publishing
Lost Money on AstraZeneca PLC (AZN)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - Stockhouse Publishing
Investors in AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN - Stockhouse Publishing
The Gross Law Firm Notifies AstraZeneca PLC Investors of a Class Action Lawsuit and Upcoming DeadlineAZN - PR Newswire
AstraZeneca gets first US approval for cancer treatment Datroway - ShareCast
AstraZeneca Plc Datroway approved in the US for metastatic breast cancer - DirectorsTalk Interviews
AstraZeneca PLC (NASDAQ:AZN) Shares Purchased by Oak Ridge Investments LLC - MarketBeat
ROSEN, THE FIRST FILING FIRM, Encourages AstraZeneca PLC - GlobeNewswire
Professional Advisory Services Inc. Raises Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca PLC (NASDAQ:AZN) Position Cut by Boston Common Asset Management LLC - MarketBeat
AstraZeneca: Diverse Clinical Pipeline Meeting Future Demand, In Undervalued Sector (NASDAQ:AZN) - Seeking Alpha
Procyon Advisors LLC Has $2.21 Million Stake in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
23,847 Shares in AstraZeneca PLC (NASDAQ:AZN) Purchased by Empirical Asset Management LLC - MarketBeat
US FDA approves AstraZeneca's drug for breast cancer - Reuters.com
AstraZeneca, Daiichi Win FDA Approval for Breast Cancer Drug - Bloomberg
2025-01-17 | Shareholders of AstraZeneca PLC Should Contact Levi & Korsinsky Before February 21, 2025 to Discuss Your RightsAZN | NDAQ:AZN | Press Release - Stockhouse Publishing
AstraZeneca Aims to Restore Trust With New Leadership in China Amid Scandal and Sales Decline - Benzinga
Novo shares high-dose Wegovy results; Amgen, AstraZeneca drugs get expanded OKs - BioPharma Dive
AstraZeneca rises Friday, still underperforms market - MarketWatch
FDA Approves AstraZeneca's Calquence Combo Therapy For Untreated Mantle Cell Lymphoma - Benzinga
Lowey Dannenberg Notifies AstraZeneca PLC (“AstraZeneca” or - GlobeNewswire
AstraZeneca changes management of its China unit (AZN:NASDAQ) - Seeking Alpha
Faruqi & Faruqi Reminds AstraZeneca Investors of the - GlobeNewswire
AstraZeneca lymphoma drug gets expanded U.S. approval (AZN) - Seeking Alpha
AstraZeneca overhauls management of its China division, FT reports -January 17, 2025 at 09:12 am EST - Marketscreener.com
AstraZeneca overhauls management of its scandal-hit China division - Financial Times
Channel Wealth LLC Purchases 23,711 Shares of AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
AstraZeneca’s Calquence Wins FDA Approval for Mantle Cell Lymphoma - TipRanks
AstraZeneca's Calquence gains FDA nod for 1L MCL treatment - Investing.com
Ritholtz Wealth Management Cuts Position in AstraZeneca PLC (NASDAQ:AZN) - MarketBeat
FDA grants full approval for AstraZeneca's Calquence - The Pharma Letter
COPD market to expand with AstraZeneca’s focus on biologics and strong portfolio growth - Pharmaceutical Technology
7MM Type 1 Diabetes Market Drug Forecast and Market Analysis 2023-2024 & 2033: Value to Reach $9.91 Billion - GlobeNewswire Inc.
AstraZeneca drug for rare blood cancer gets US regulatory green light - Proactive Investors USA
AstraZeneca: Calquence approved for LCM by the FDA -January 17, 2025 at 03:00 am EST - Marketscreener.com
AZN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
FDA approves AstraZeneca's Calquence for untreated mantle cell lymphoma By Investing.com - Investing.com UK
AstraZeneca's rare cancer drug Calquence gets US regulatory nod - ShareCast
AstraZeneca PLC (NASDAQ:AZN) Short Interest Update - MarketBeat
AZN Class Action Notice: Robbins LLP Reminds Stockholders of the Lead Plaintiff Deadline in the AstraZeneca PLC Class Action - PR Newswire
AZN Investors Have Opportunity to Lead AstraZeneca PLC Securities Fraud Lawsuit Filed by The Rosen Law Firm - PR Newswire
AstraZeneca PLC ADR outperforms market on strong trading day - MarketWatch
AstraZeneca rises Thursday, outperforms market - MarketWatch
大文字化:
|
ボリューム (24 時間):